The Use of Oxymetazoline 0.1% Ophthalmic Solution for Acquired Blepharoptosis: A Systematic Review.
MRD1
blepharoptosis
meta‐analysis
oxymetazoline
ptosis
systematic review
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
revised:
26
07
2024
received:
06
03
2024
accepted:
29
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
Oxymetazoline hydrochloride has been shown to be effective in some studies for acquired blepharoptosis and for aesthetic upper eyelid elevation. This study aims to systematically review the literature on the use of topical oxymetazoline for treating acquired blepharoptosis. PubMed (U.S. National Library of Medicine, National Institutes of Health), Scopus (Elsevier), and Cochrane. A systematic review of studies published between 2013 and 2024 following PRISMA guidelines was performed using the PubMed, Scopus, and Cochrane databases. Primary outcomes included pre- to posttreatment change in marginal reflex distance (MRD1) after treatment with topical oxymetazoline, and mean difference (pre-to-posttreatment) in MRD1 versus control. Five articles included data from 458 patients for analysis. Meta-analysis demonstrated significant improvement in MRD1 measurements posttreatment with oxymetazoline (1.40 mm; 95% confidence interval, CI [0.41 mm, 2.40 mm]). In addition, when compared to controls, patients treated with oxymetazoline demonstrated greater increase in MRD1 values (0.83 mm; 95% CI [0.10 mm, 1.55 mmm]). Heterogeneity, measured by I The use of oxymetazoline 0.1% ophthalmic solution significantly improves MRD1 in patients with acquired blepharoptosis. Further studies comparing this treatment in other etiologies of acquired blepharoptosis should be conducted. Laryngoscope, 2024.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.
Références
Wirta DL, Korenfeld MS, Foster S, et al. Safety of once‐daily oxymetazoline HCl ophthalmic solution, 0.1% in patients with acquired blepharoptosis: results from four randomized, double‐masked clinical trials. Clin Ophthalmol. 2021;15:4035‐4048.
Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020;11:1168‐1175.
Bacharach J, Wirta DL, Smyth‐Medina R, et al. Rapid and sustained eyelid elevation in acquired blepharoptosis with oxymetazoline 0.1%: randomized phase 3 trial results. Clin Ophthalmol. 2021;15:2743‐2751.
Safi M, Bacharach J. Upneeq for the treatment of speculum‐induced blepharoptosis. JCRS Online Case Rep. 2021;9(2):e00048. https://doi.org/10.1097/j.jcro.0000000000000048.
Shoji MK, Markatia Z, Ameli K, et al. The effects of topical oxymetazoline on eyelid position, eye redness, and patient‐reported eye appearance: a randomized controlled trial. J Plast Reconstr Aesthet Surg. 2023;80:66‐74.
Ugradar S, Kim JS, Trost N, et al. Changes to eye whiteness and eyelid/brow position with topical oxymetazoline in aesthetic patients. Aesthet Surg J. 2022;6:582‐589.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan – a web and mobile app for systematic reviews. Syst Rev. 2016;1:210.
Huang X, Lin J, Demner‐Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annual Symposium Proceedings 2006, Vol. 2006. American Medical Informatics Association:359.
CEBM (Centre for Evidence‐Based Medicine). Oxford centre for evidence‐based medicine—levels of evidence (March 2009). 2009. Accessed June 30, 2024. http://www.cebm.net/index.aspx?o=1025.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed‐effect and random‐effects models for meta‐analysis. Res Synth Methods. 2010;1(2):97‐111. https://doi.org/10.1002/jrsm.12
Finsterer J. Ptosis: causes, presentation, and management. Aesthetic Plast Surg. 2003;27(3):193‐204. https://doi.org/10.1007/s00266-003-0127-5.
Briceño CA, Fuller ML, Bradley EA, Nelson CC. Assessment of the abbreviated National eye Institute visual function questionnaire (NEI VFQ 9) in blepharoptosis and dermatochalasis. Arq Bras Oftalmol. 2016;4:226‐228.
Ludwig GD, Osaki MH, Gameiro GR, Hentona OT. Is it worth using botulinum toxin injections for the management of mild to moderate blepharoptosis? Aesthet Surg J. 2022;42(12):1377‐1381. https://doi.org/10.1093/asj/sjac139.
Shokri TPS, Ziai K, Harounian J, Lighthall JG. Facial synkinesis: a distressing sequela of facial palsy. Ear Nose Throat J. 2021;103:NP382‐NP391. https://doi.org/10.1177/01455613211054627.
Karam M, Alsaif A, Abul A, et al. Muller's muscle conjunctival resection versus external levator advancement for ptosis repair: systematic review and meta‐analysis. Int Ophthalmol. 2023;7:2563‐2573.
Thomas GN, Chan J, Sundar G, Amrith S. Outcomes of levator advancement and Müller muscle‐conjunctiva resection for the repair of upper eyelid ptosis. Orbit. 2017;36(1):39‐42. https://doi.org/10.1080/01676830.2017.1279650.
Sweeney AR, Dermarkarian CR, Williams KJ, Allen RC, Yen MT. Outcomes after Müller muscle conjunctival resection versus external levator advancement in severe involutional blepharoptosis. Am J Ophthalmol. 2020;217:182‐188.
Hwang K, Ko YS. Improvement of the marginal reflex distance‐1 in blepharoptosis surgeries. J Craniofac Surg. 2016;27(2):455‐460. https://doi.org/10.1097/SCS.0000000000002348.
Hakimbashi M, Kikkawa DO, Korn BS. Complications of ptosis repair: prevention and management. In: Cohen AJ, Weinberg DA, eds. Evaluation and Management of Blepharoptosis. Springer: New York; 2011:275‐287.
Hellman A, Torres‐Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord. 2015;8(2):82‐91.
Sung J, Song A, Song M, Song J. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series. J Med Case Reports. 2022;16:299. https://doi.org/10.1186/s13256-022-03493-6.